Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20090030309 A1
Publication typeApplication
Application numberUS 12/070,786
Publication date29 Jan 2009
Filing date21 Feb 2008
Priority date26 Jul 2007
Also published asCA2715743A1, CN101977561A, EP2244653A1, US9149341, US20090216118, US20120078092, US20120116215, WO2009105177A1
Publication number070786, 12070786, US 2009/0030309 A1, US 2009/030309 A1, US 20090030309 A1, US 20090030309A1, US 2009030309 A1, US 2009030309A1, US-A1-20090030309, US-A1-2009030309, US2009/0030309A1, US2009/030309A1, US20090030309 A1, US20090030309A1, US2009030309 A1, US2009030309A1
InventorsMichael L. Jones, Paul Lubock
Original AssigneeSenorx, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Deployment of polysaccharide markers
US 20090030309 A1
Abstract
The marker member delivery system described has a plurality of marker members disposed within a delivery tube or cannula which contain a suitable polysaccharide such as starch (e.g. corn starch or potato starch) and a binder such as methylcellulose. These marker members are preferably press-formed from powders. The system has preferably has at least one other marker member formed of bioabsorbable material with a radiopaque element attached to or incorporated therein. The marker with a radiopaque marker element is preferably disposed within the delivery tube between two marker members formed of polysaccharide and is preferably formed of a bioabsorbable material other than a polysaccharide.
Images(2)
Previous page
Next page
Claims(17)
1. A method for treating a site within a patient from which tissue has been removed, comprising:
a. providing at least one press-formed marker body formed of polysaccharide and a suitable binder;
b. placing at least one of the press-formed marker bodies within the site where tissue has been removed so as to provide hemostasis therein.
2. The method of claim 1 wherein the press-formed body is formed of a mixed powder of polysaccharide and binder.
3. The method of claim 2 wherein the powder has a particle size less than 0.01 inch.
4. The method of claim 2 wherein the powder has a particle size of about 10 to about 200 micrometers.
5. The method of claim 1 wherein the press-formed body has a transverse dimension of about 0.02 to about 0.1 inch.
6. The method of claim 1 wherein the press-formed body has a transverse dimension of about 0.035 to about 0.075 inch.
7. The method of claim 1 wherein the press-formed body has a length of about 0.1 to about 0.4 inch.
8. The method of claim 1 wherein the press-formed body has a length of about 0.15 to about 0.35 inch.
9. The method of claim 1 wherein a plurality of marker members which comprise a bioabsorbable polysaccharide in sufficient amounts to exhibit hemostatic properties and a binder are disposed within an inner lumen of a tubular delivery member and are urged out a discharge port in the tubular delivery member.
10. The method of claim 9 wherein the marker members are about 10 to about 90% (by wt.) bioabsorbable polysaccharide.
11. The method of claim 1 wherein the marker members are formed of a polysaccharide selected from the group consisting of starch, glycogen, cellulose, chitin, chitosan, dextran, pectins, glucans, agar, alginate and carrageen.
12. The method of claim 11 wherein the marker members are formed of corn starch or potato starch.
13. The method of claim 9 wherein the marker members are about 10 to about 90% (by wt.) binder.
14. The method of claim 13 wherein the marker members are formed of a binder selected from the group consisting of methycellulose, hydroxyethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinylpyrolidone.
15. The method of claim 13 wherein the marker members are formed of a binder comprising methycellulose.
16. The method of claim 9 wherein the marker members are press-formed into a desired shape.
17. The method of claim 1 wherein plunger is slidably disposed within the inner lumen of the delivery tube and is provided with a head on a proximal end thereof to allow an operator to press the plunger further into the inner lumen and push both the releasable plug and marker members and marker body out of a discharge port or opening in a distal portion of delivery cannula.
Description
    RELATED APPLICATIONS
  • [0001]
    This application is related to and claims priority from provisional application Ser. No. 60/835,740, filed on Aug. 4, 2006, and copending application Ser. No. 11/881,264, filed on Jul. 26, 2007, both of which are incorporated herein by reference in their entirety.
  • FIELD OF THE INVENTION
  • [0002]
    The invention is generally directed to remotely detectable, intracorporeal markers and devices and methods for the delivery of such markers to a desired location within a patient's body.
  • BACKGROUND OF THE INVENTION
  • [0003]
    In diagnosing and treating certain medical conditions, it is often desirable to mark a suspicious body site for the subsequent taking of a biopsy specimen, for delivery of medicine, radiation, or other treatment, for the relocation of a site from which a biopsy specimen was taken, or at which some other procedure was performed. As is known, obtaining a tissue sample by biopsy and the subsequent examination are typically employed in the diagnosis of cancers and other malignant tumors, or to confirm that a suspected lesion or tumor is not malignant. The information obtained from these diagnostic tests and/or examinations is frequently used to devise a therapeutic plan for the appropriate surgical procedure or other course of treatment.
  • [0004]
    In many instances, the suspicious tissue to be sampled is located in a subcutaneous site, such as inside a human breast. To minimize surgical intrusion into a patient's body, it is often desirable to insert a small instrument, such as a biopsy needle, into the body for extracting the biopsy specimen while imaging the procedure using fluoroscopy, ultrasonic imaging, x-rays, magnetic resonance imaging (MRI) or any other suitable form of imaging technique or palpation. Examination of tissue samples taken by biopsy is of particular significance in the diagnosis and treatment of breast cancer. In the ensuing discussion, the biopsy and treatment site described will generally be the human breast, although the invention is suitable for marking biopsy sites in other parts of the human and other mammalian body as well.
  • [0005]
    Periodic physical examination of the breasts and mammography are important for early detection of potentially cancerous lesions. In mammography, the breast is compressed between two plates while specialized x-ray images are taken. If an abnormal mass in the breast is found by physical examination or mammography, ultrasound may be used to determine whether the mass is a solid tumor or a fluid-filled cyst. Solid masses are usually subjected to some type of tissue biopsy to determine if the mass is cancerous.
  • [0006]
    If a solid mass or lesion is large enough to be palpable, a tissue specimen can be removed from the mass by a variety of techniques, including but not limited to open surgical biopsy, a technique known as Fine Needle Aspiration Biopsy (FNAB) and instruments characterized as “vacuum assisted large core biopsy devices”.
  • [0007]
    If a solid mass of the breast is small and non-palpable (e.g., the type typically discovered through mammography), a vacuum assisted large core biopsy procedure is usually used. In performing a stereotactic biopsy of a breast, the patient lies on a special biopsy table with her breast compressed between the plates of a mammography apparatus and two separate x-rays or digital video views are taken from two different points of view. A computer calculates the exact position of the lesion as well as depth of the lesion within the breast. Thereafter, a mechanical stereotactic apparatus is programmed with the coordinates and depth information calculated by the computer, and such apparatus is used to precisely advance the biopsy needle into the small lesion. The stereotactic technique may be used to obtain histologic specimens. Usually at least five separate biopsy specimens are obtained from locations around the small lesion as well as one from the center of the lesion.
  • [0008]
    The available treatment options for cancerous lesions of the breast include various degrees of mastectomy or lumpectomy, radiation therapy, chemotherapy and combinations of these treatments. However, radiographically visible tissue features, originally observed in a mammogram, may be removed, altered or obscured by the biopsy procedure, and may heal or otherwise become altered following the biopsy. In order for the surgeon or radiation oncologist to direct surgical or radiation treatment to the precise location of the breast lesion several days or weeks after the biopsy procedure was performed, it is desirable that a biopsy site marker be placed in the patient's body to serve as a landmark for subsequent location of the lesion site. A biopsy site marker may be a permanent marker (e.g., a metal marker visible under x-ray examination), or a temporary marker (e.g., a bioresorbable marker detectable with ultrasound). While current radiographic type markers may persist at the biopsy site, an additional mammography generally must be performed at the time of follow up treatment or surgery in order to locate the site of the previous surgery or biopsy. In addition, once the site of the previous procedure is located using mammography, the site must usually be marked with a location wire which has a hook on the end which is advanced into site of the previous procedure. The hook is meant to fix the tip of the location wire with respect to the site of the previous procedure so that the patient can then be removed from the confinement of the mammography apparatus and the follow-up procedure performed. However, as the patient is removed from the mammography apparatus, or otherwise transported the position of the location wire can change or shift in relation to the site of the previous procedure. This, in turn, can result in follow-up treatments being misdirected to an undesired portion of the patient's tissue.
  • [0009]
    As an alternative or adjunct to radiographic imaging, ultrasonic imaging (herein abbreviated as “USI”) or visualization techniques can be used to image the tissue of interest at the site of interest during a surgical or biopsy procedure or follow-up procedure. USI is capable of providing precise location and imaging of suspicious tissue, surrounding tissue and biopsy instruments within the patient's body during a procedure. Such imaging facilitates accurate and controllable removal or sampling of the suspicious tissue so as to minimize trauma to surrounding healthy tissue.
  • [0010]
    For example, during a breast biopsy procedure, the biopsy device is often imaged with USI while the device is being inserted into the patient's breast and activated to remove a sample of suspicious breast tissue. As USI is often used to image tissue during follow-up treatment, it may be desirable to have a marker, similar to the radiographic markers discussed above, which can be placed in a patient's body at the site of a surgical procedure and which are visible using USI. Such a marker enables a follow-up procedure to be performed without the need for traditional radiographic mammography imaging which, as discussed above, can be subject to inaccuracies as a result of shifting of the location wire as well as being tedious and uncomfortable for the patient.
  • [0011]
    Placement of a marker or multiple markers at a location within a patient's body requires delivery devices capable of holding markers within the device until the device is properly situated within a breast or other body location. Accordingly, devices and methods for retaining markers within a marker delivery device while allowing their expulsion from the devices at desired intracorporeal locations are desired.
  • [0012]
    In addition to marking functions, frequently it is desirable to provide treatments with the marker members such as hemostatic treatment and the like.
  • SUMMARY OF THE INVENTION
  • [0013]
    The invention is generally directed to a remotely imageable marker system suitable for deployment at a site within a patient's body, particularly a biopsy site such as in a patient's breast. The imageable marker system has a plurality of marker members containing polysaccharide in sufficient amounts to provide hemostatic properties and has a molecular weight of about 3500 to about 200,000 Daltons. The polysaccharide containing marker members are preferably press-formed from a dry powder into a pellet shape. The polysaccharide and binder powder should have a particle size of about 10 to about 200 micrometers. The polysaccharide markers rapidly absorb body fluid and hydrate and in the process dehydrate blood at the site of deployment to rapidly initiate clotting.
  • [0014]
    The polysaccharide is preferably starch (corn starch or potato starch) but a variety of bioabsorbable polysaccharides are suitable, including glycogen, cellulose, chitin, chitosan, dextran, pectins, glucans, agar, alginate and carrageen. The binder is preferably methycellulose but a variety of binders may be employed in lieu of or in addition to methycellulose. Other suitable binders include hydroxyethyl cellulose, polyethylene glycol, polyvinyl alcohol, polyvinylpyrolidone.
  • [0015]
    The remotely imageable marker system preferably includes a marker body with a radiopaque element connected thereto or incorporated therein to provide long term identification of the intracorporeal site. Preferably, the radiopaque element is formed of non-magnetic material to avoid interference with magnetic resonance imaging (MRI). Suitable non-magnetic materials include titanium, platinum, gold, iridium, tantalum, tungsten, silver, rhodium, non-magnetic stainless steel (316) and the like. The radiopaque element should have a shape that is readily recognized at the intracorporeal site when remotely imaged. The radiopaque element should have a maximum dimension of about 0.5 to about 5 mm, preferably about 1 to about 3 mm to ensure remote identification, particularly with MRI. The marker body having a radiopaque element is preferably formed of a bioabsorbable polymeric material such as polylactic-polyglycolic acid (polylactide-co-glycolide) with a longer dissolution time than the polysaccharide pellets, although the latter may be used.
  • [0016]
    The polysaccharide containing pellets will generally have a transverse dimension of about 0.02 to about 0.1 inch (0.5-2.5 mm), preferably about 0.035 to about 0.075 inch (0.9-1.9 mm), and typically about 0.056 inch (1.4 mm). The pellets will have a length of about 0.1 to about 0.4 inch (2.5-10 mm), preferably about 0.15 to about 0.35 inch (3.8-8.9 mm). The pellets provide sufficient column strength to facilitate introduction into and discharge thereof from the tubular delivery device. The markers are preferably arranged for delivery within the delivery tube with the marker having a radiopaque element between two adjacent marker members formed of polysaccharide. As presently contemplated, within the delivery tube there will be two polysaccharide marker members distal and two polysaccharide marker members proximal to the marker having a radiopaque element.
  • [0017]
    The marker member embodying features of the invention can be readily delivered to the desired location by suitable delivery systems such as disclosed in co-pending application Ser. No. 10/444,770, filed on May 23, 2003 and Ser. No. 10/753,277, filed on Dec. 23, 2003. The marker delivery system generally has an elongated cannula or tube with proximal and distal ports and an inner lumen extending between the ports. The marker member is slidably disposed within the inner lumen of the delivery cannula and a plunger slidably disposed within the inner lumen of the delivery cannula proximal to the markers. The plunger is movable from an initial position proximal to the markers within the tube, to a delivery position close to the discharge opening in the distal end of the cannula to push the marker members out of the discharge opening into the target tissue site.
  • [0018]
    Upon being discharged into the intracorporeal target site, the plurality of polysaccharide containing markers quickly take up body fluid at the site, initiating the clotting process and providing hemostasis. The other marker member with a radiopaque marker element enables short term detection (at least three weeks, preferably at least four weeks but less than a year) by remote USI and preferably long term detection by remote mammographic imaging or MRI identification by the radiopaque element. Typically, the polysaccharide bodies dissolve in situ in about five seconds to about 2 minutes and enzymatically degrade in about 2-5 days.
  • [0019]
    The cannula of the marker delivery device may be configured to fit within the guide cannula of a biopsy device, such as a Mammotome® (sold by Johnson & Johnson), the SenoCor 360™ biopsy device sold by SenoRx (the present assignee), the EnCor™ biopsy device sold by SenoRx and or a coaxial needle guide. The delivery cannula can also be configured to fit into the proximal end of a tubular cutting element such as found in the EnCor™ biopsy system sold by SenoRx which is the subject of co-pending application Ser. No. 10/911,106, filed on Aug. 3, 2004.
  • [0020]
    One suitable delivery system suitable for delivery through a tubular cutter (e.g. as with the Encor™ system) is a syringe-type delivery system described in co-pending application Ser. No. 10/911,106, filed on Aug. 3, 2004 having a tubular shaft with a flared guide on or integral with the distal tip to facilitate engagement with the proximal end of the tubular cutter. Another syringe-type delivery system has a plugged distal tip to prevent body fluids from engaging one or more markers which may be in the tubular shaft of the delivery system. Such fluid infusions can retard or restrict discharging the markers within the inner lumen of the delivery cannula by causing the markers to take up water or swell within the lumen of the delivery cannula. Delivery systems with plugged tips are described in co-pending application Ser. No. 10/444,770, filed on May 23, 2003 and Ser. No. 10/753,277, filed on Dec. 23, 2003, which are incorporated herein in their entireties. The plugged tip type delivery systems can have a side opening for marker deployment or a plugged needle-type distal tip both of which are disclosed in the above application Ser. No. 10/753,694.
  • [0021]
    A variety of therapeutic or diagnostic agents may also be incorporated into the marker bodies. Incorporated agents can include for example, anesthetic agents to control pain, chemotherapeutic agents for treating residual neoplastic tissue or coloring agents to facilitate subsequent visual location of the site. Antibiotics, antifungal agents and antiviral agents may also be incorporated into the marker bodies.
  • [0022]
    Upon delivery to the intracorporeal site, the markers are easily identifiable from surrounding tissue at the site by ultrasonic imaging (USI).
  • [0023]
    The polysaccharide containing markers embodying features of the present invention provide several advantages. The polysaccharide marker bodies quickly dissolve in the body fluids at the site to provide to provide rapid hemostasis therein even with serious bleeding. Moreover, the materials rapidly degrade so there is no long term irritation or inflammation at the site.
  • [0024]
    These and other advantages of the invention will become more apparent from the following detailed description of embodiments when taken in conjunction with the accompanying exemplary drawings.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0025]
    FIG. 1 is a plan view of a press-formed marker member embodying features of the invention.
  • [0026]
    FIG. 2 is an end view of the marker member shown in FIG. 1.
  • [0027]
    FIG. 3 is a perspective view of a plurality of markers arranged as they would be within a delivery tube (not shown).
  • [0028]
    FIG. 4 is a partly cut-away perspective view of a marker delivery assembly having a plurality of marker members embodying features of the invention.
  • [0029]
    FIG. 5 is a transverse cross-sectional view taken along the lines 5-5 shown in FIG. 4.
  • DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION
  • [0030]
    FIGS. 1 and 2 illustrate a press-formed marker member 10 embodying features of the invention which is formed of a mixture of polysaccharide powder and methylcellulose powder. The press-formed marker member 10 has sufficient polysaccharide powder so as to quickly form thrombus when coming into contact with blood at an intracorporeal site. Typically, the marker member 10 will have 65% (by wt.) polysaccharide and 35% (by wt.) methylcellulose. The marker member 10 is preferably formed by mixing polysaccharide powder (corn starch or potato starch) and methylcellulose powder in appropriate amounts, placing the mixed powder in a pellet die and subjecting the powder within the pellet die to a pressure of about 6 to 40 ksi, typically about 12 ksi.
  • [0031]
    One suitable polysaccharide material is U.S.P. Topical Starch. Alternatively, Hemaderm™, which is available from Medafor, Inc. located in Minneapolis, Minn., may also be used. This product is described at least in part in U.S. Pat. No. 6,060,461.
  • [0032]
    The marker member 10 may be formed in a variety of shapes and sizes, but generally the length of the marker member is at least twice, preferably five times that of the maximum transverse dimension. The marker member 10 should have sufficient column strength to allow it to be pushed within the delivery tube without significant damage. In some instances the marker member may be partially or completely coated with a bioabsorbable polymeric material such as polylactic acid, polyglycolic acid and copolymers thereof to control the dissolution of the material of the marker member.
  • [0033]
    One suitable marker delivery system 15 is depicted in FIGS. 4A-4B which includes a delivery tube or cannula 16 with an inner lumen 17, a distal portion 18, and a proximal portion 19 with a handle 20. A releasable distal plug 21 and the press-formed markers 10 are shown disposed within the inner lumen 17. A marker body 22 formed of a bioabsorbable material other than a polysaccharide with a radiopaque element is disposed between at least two press-formed marker bodies 10. A plunger 23 is slidably disposed within the inner lumen 17 and is provided with a head 24 on the proximal end 25 configured to allow an operator to press the plunger further into the inner lumen and push both the releasable plug 21 and marker members 10 and marker body 22 out of the discharge port or opening 26 in the distal end 27 of delivery cannula 16. Cannula handle 20 allows an operator to hold the cannula steady while pressing plunger 23 to discharge the releasable plug 21 and marker members 10 and marker body 22.
  • [0034]
    Releasable plug 21, preferably formed of polyethylene glycol, may substantially fill the discharge opening 26, as shown in FIG. 4A or at least occupy or block a portion of the discharge opening. The exposed face of plug 21 is preferably provided with an inclined configuration. Releasable plug 21 is configured to be tight enough, e.g. press fit, in the inner lumen 17 to prevent its inadvertent release which might allow premature discharge of marker 10 from delivery cannula 16, but the plug must be easily released when the plunger 23 is pressed deeper into the inner lumen 17 of the delivery cannula 16. An adhesive or mechanical element(s) may be used to hold the releasable plug 21 in a position within the inner lumen 17 to occlude the discharge opening 26. Suitable adhesives include polyurethane or polyacrylic based adhesives, polyhydroxymethacrylate base adhesives, fibrin glue (e.g., Tisseal™), collagen adhesive, or mixtures thereof. Suitable mechanical means for securing the releasable plug 21 are described in co-pending application Ser. No. 10/174,401. The distal end 26 of the delivery cannula 16 is provided with a ramp 27 which guides the discharged plug 21 and marker member 10 out of the side port 28 into the target site. The distal tip 29 may be tapered for delivery through a guide tube (not shown).
  • [0035]
    The delivery cannula 16 may be provided with markings 30 which serve as visual landmarks to aid an operator in accurately placing the distal portion 18 of the cannula 16 in a desired location within a patient's body for discharging the marker 10.
  • [0036]
    The exterior of the delivery cannula 16 is preferably configured to fit within a guide cannula sized to accept a SenoCor®, EnCor™, Mammotome® or Tru-Cut®, biopsy device. Typically, plug 21 and marker member 10 will have diameters determined by the size of the inner lumen 17 and typically will be about 0.02 inch (0.5 mm) to about 0.5 inch (12 mm), preferably about 0.04 inch (1 mm) to about 0.3 inch (8 mm). Plug 21 may have slightly larger transverse dimensions to provide a tight fit.
  • [0037]
    When the marker member 10 contacts body fluid within a body cavity such as a lumpectomy or biopsy site, the binding agent is dissolved and the polysaccharide draws moisture away from the blood and other fluids at the site and the clotting cascade begins to form thrombus at the site resulting in hemostasis.
  • [0038]
    While one or more particular forms of the invention have been illustrated and described herein in the context of a breast biopsy site, it will be apparent that the device and methods having features of the invention may find use in a variety of locations and in a variety of applications, in addition to the human breast, where tissue has been removed. Moreover, various modifications can be made without departing from the spirit and scope of the invention. For example, while the polysaccharide bodies are primarily described herein as press-formed bodies, the polysaccharide materials by be encapsulated in a bioabsorbable body or be in other forms. Accordingly, it is not intended that the invention be limited to the specific embodiments illustrated. It is therefore intended that this invention to be defined by the scope of the appended claims as broadly as the prior art will permit, and in view of the specification if need be. Moreover, those skilled in the art will recognize that features shown in one embodiment may be utilized in other embodiments. Additional details of pellet or other marker members and delivery systems may be found in co-pending application Ser. No. 10/753,694, filed on Jan. 7, 2004, and Ser. No. 10/976,138, filed on Oct. 27, 2004.
  • [0039]
    Terms such as “element”, “member”, “device”, “section”, “portion”, “step”, “means” and words of similar import when used in the following claims shall not be construed as invoking the provisions of 35 U.S.C. §112(6) unless the following claims expressly use the term “means” followed by a particular function without specific structure or expressly use the term “step” followed by a particular function without specific action. All patents and patent applications referred to above are hereby incorporated by reference in their entirety.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2192270 *25 May 19385 Mar 1940American Brake CoBrake rigging
US3593343 *19 Jul 196820 Jul 1971Viggers Robert FProsthetic ball-check heart valve
US3818894 *3 Jan 197225 Jun 1974Ceskoslovenska Akademie VedLaryngeal implant
US3823212 *28 May 19719 Jul 1974Freudenberg C FaProcess for the production of collagen fiber fabrics in the form of felt-like membranes or sponge-like layers
US4007732 *2 Sep 197515 Feb 1977Robert Carl KvavleMethod for location and removal of soft tissue in human biopsy operations
US4197846 *25 Jun 197515 Apr 1980Louis BucaloMethod for structure for situating in a living body agents for treating the body
US4276885 *4 May 19797 Jul 1981Rasor Associates, IncUltrasonic image enhancement
US4331654 *13 Jun 198025 May 1982Eli Lilly And CompanyMagnetically-localizable, biodegradable lipid microspheres
US4390018 *17 May 198228 Jun 1983Zukowski Henry JMethod for preventing loss of spinal fluid after spinal tap
US4647480 *1 Aug 19853 Mar 1987Amchem Products, Inc.Use of additive in aqueous cure of autodeposited coatings
US4813062 *13 Aug 198614 Mar 1989Milliken Research CorporationRadio-opaque marker and method
US4832686 *24 Jun 198623 May 1989Anderson Mark EMethod for administering interleukin-2
US4847049 *20 Mar 198711 Jul 1989Vitaphore CorporationMethod of forming chelated collagen having bactericidal properties
US4909250 *14 Nov 198820 Mar 1990Smith Joseph RImplant system for animal identification
US4938763 *3 Oct 19883 Jul 1990Dunn Richard LBiodegradable in-situ forming implants and methods of producing the same
US5081997 *20 Jul 198921 Jan 1992Vance Products IncorporatedEchogenic devices, material and method
US5221269 *15 Oct 199022 Jun 1993Cook IncorporatedGuide for localizing a nonpalpable breast lesion
US5281197 *27 Jul 199225 Jan 1994Symbiosis CorporationEndoscopic hemostatic agent delivery system
US5281408 *19 Jan 199325 Jan 1994Unger Evan CLow density microspheres and their use as contrast agents for computed tomography
US5282781 *25 Oct 19901 Feb 1994Omnitron International Inc.Source wire for localized radiation treatment of tumors
US5289831 *21 Apr 19921 Mar 1994Vance Products IncorporatedSurface-treated stent, catheter, cannula, and the like
US5320613 *6 Jan 199314 Jun 1994Scimed Life Systems, Inc.Medical lumen flushing and guide wire loading device and method
US5394875 *21 Oct 19937 Mar 1995Lewis; Judith T.Automatic ultrasonic localization of targets implanted in a portion of the anatomy
US5395319 *29 Feb 19927 Mar 1995Suddeutsche Feinmechanik GmbhNeedle for inserting an object into the body
US5422730 *25 Mar 19946 Jun 1995Barlow; Clyde H.Automated optical detection of tissue perfusion by microspheres
US5425366 *7 Jun 199320 Jun 1995Schering AktiengesellschaftUltrasonic contrast agents for color Doppler imaging
US5433204 *16 Nov 199318 Jul 1995Camilla OlsonMethod of assessing placentation
US5494030 *12 Aug 199327 Feb 1996Trustees Of Dartmouth CollegeApparatus and methodology for determining oxygen in biological systems
US5508021 *19 Oct 199416 Apr 1996Vivorx Pharmaceuticals, Inc.Non-fluorinated polymeric shells for medical imaging
US5538726 *19 Jan 199423 Jul 1996Order; Stanley E.Method and compositions for delivering cytotoxic agents to cancer
US5629008 *7 Jun 199413 May 1997C.R. Bard, Inc.Method and device for long-term delivery of drugs
US5636255 *5 Mar 19963 Jun 1997Queen's University At KingstonMethod and apparatus for CT image registration
US5643246 *24 Feb 19951 Jul 1997Gel Sciences, Inc.Electromagnetically triggered, responsive gel based drug delivery device
US5646146 *25 May 19958 Jul 1997Novo Nordisk A/SHeterocyclic compounds and their preparation and use
US5747060 *26 Mar 19965 May 1998Euro-Celtique, S.A.Prolonged local anesthesia with colchicine
US5762903 *8 Mar 19969 Jun 1998Korea Atomic Energy Research InstituteRadioactive chitosan complex for radiation therapy
US5782775 *14 Jun 199621 Jul 1998United States Surgical CorporationApparatus and method for localizing and removing tissue
US5902310 *21 Feb 199711 May 1999Ethicon Endo-Surgery, Inc.Apparatus and method for marking tissue
US6015541 *3 Nov 199718 Jan 2000Micro Therapeutics, Inc.Radioactive embolizing compositions
US6030333 *24 Oct 199729 Feb 2000Radiomed CorporationImplantable radiotherapy device
US6056700 *13 Oct 19982 May 2000Emx, Inc.Biopsy marker assembly and method of use
US6071301 *1 May 19986 Jun 2000Sub Q., Inc.Device and method for facilitating hemostasis of a biopsy tract
US6071310 *23 Nov 19986 Jun 2000George J. PichaSpinal implant
US6071496 *7 Jun 19956 Jun 2000Scharing AktiengesellschaftPolyalkylcyanoacrylate agents and methods for enhancing contrast in ultrasound imaging
US6177062 *7 Jun 199523 Jan 2001Schering AktiengesellschaftAgents and methods for enhancing contrast in ultrasound imaging
US6181960 *15 Jan 199930 Jan 2001University Of Virginia Patent FoundationBiopsy marker device
US6183497 *17 Jun 19996 Feb 2001Sub-Q, Inc.Absorbable sponge with contrasting agent
US6214315 *10 Sep 199910 Apr 2001Micro Therapeutics IncRadioactive embolizing compositions
US6220248 *21 Oct 199824 Apr 2001Ethicon Endo-Surgery, Inc.Method for implanting a biopsy marker
US6224630 *29 May 19981 May 2001Advanced Bio Surfaces, Inc.Implantable tissue repair device
US6228055 *19 May 19978 May 2001Ethicon Endo-Surgery, Inc.Devices for marking and defining particular locations in body tissue
US6231615 *18 Oct 199915 May 2001Parallax Medical, Inc.Enhanced visibility materials for implantation in hard tissue
US6234177 *12 Aug 199922 May 2001Thomas BarschApparatus and method for deploying an expandable biopsy marker
US6251418 *18 Dec 199726 Jun 2001C.R. Bard, Inc.Systems and methods for local delivery of an agent
US6261302 *26 Jun 199817 Jul 2001Ethicon Endo-Surgery, Inc.Applier for implantable surgical marker
US6336904 *6 Apr 19998 Jan 2002Pro Duct Health, Inc.Methods and devices for the localization of lesions in solid tissue
US6347241 *30 Jun 199912 Feb 2002Senorx, Inc.Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it
US6350244 *21 Feb 200026 Feb 2002Biopsy Sciences, LlcBioabsorable markers for use in biopsy procedures
US6356782 *2 Apr 199912 Mar 2002Vivant Medical, Inc.Subcutaneous cavity marking device and method
US6371904 *2 Jul 199916 Apr 2002Vivant Medical, Inc.Subcutaneous cavity marking device and method
US6394965 *15 Aug 200028 May 2002Carbon Medical Technologies, Inc.Tissue marking using biocompatible microparticles
US6427081 *5 Sep 200030 Jul 2002Senorx, Inc.Methods and chemical preparations for time-limited marking of biopsy sites
US6511468 *31 Aug 199928 Jan 2003Micro Therapeutics, Inc.Device and method for controlling injection of liquid embolic composition
US6537193 *30 Oct 200025 Mar 2003Scimed Life Systems, Inc.Method and device for delivery of therapeutic agents in conjunction with isotope seed placement
US6540981 *11 Dec 20001 Apr 2003Amersham Health AsLight imaging contrast agents
US6544185 *23 Oct 20018 Apr 2003Valentino MontegrandeUltrasound imaging marker and method of use
US6554760 *24 Oct 200129 Apr 2003Gary A. LamoureuxPre-loaded needle assembly
US6562317 *20 Feb 200113 May 2003Micro Therapeutics, Inc.Radioactive embolizing compositions
US6565551 *23 Nov 199820 May 2003Micro Therapeutics, Inc.Contoured syringe and novel luer hub and methods for embolizing blood vessels
US6567689 *27 Feb 200220 May 2003Senorx, Inc.Methods and chemical preparations for time-limited marking of biopsy sites
US6575888 *24 Jan 200110 Jun 2003Biosurface Engineering Technologies, Inc.Bioabsorbable brachytherapy device
US6712836 *12 May 200030 Mar 2004St. Jude Medical Atg, Inc.Apparatus and methods for closing septal defects and occluding blood flow
US6725083 *20 Nov 200020 Apr 2004Senorx, Inc.Tissue site markers for in VIVO imaging
US6746661 *18 May 20018 Jun 2004Microspherix LlcBrachytherapy seed
US6766186 *16 Jun 199920 Jul 2004C. R. Bard, Inc.Post biospy tissue marker and method of use
US6862470 *16 Apr 20021 Mar 2005Senorx, Inc.Cavity-filling biopsy site markers
US7172549 *29 Mar 20046 Feb 2007Slater Charles RRadioactive therapeutic seed having selective marker configuration
US20010003791 *30 Jun 199914 Jun 2001Heller Ehrman White & McauliffeUltrasonic and x-ray detectable biopsy site marker and apparatus for applying it
US20010006616 *2 Oct 19975 Jul 2001D Leavitt RichardPolymeric delivery of radionuclides and radiopharmaceuticals
US20020035324 *13 Mar 200121 Mar 2002Sirimanne D. LaksenSubcutaneous cavity marking device and method
US20020038087 *31 Oct 200128 Mar 2002Senorx, Inc.Imageable biopsy site marker
US20020052572 *25 Sep 20012 May 2002Kenneth FrancoResorbable anastomosis stents and plugs and their use in patients
US20020058882 *30 Nov 200116 May 2002Artemis Medical, IncorporatedBiopsy localization method and device
US20020095205 *12 Jan 200118 Jul 2002Edwin Tarun J.Encapsulated radiopaque markers
US20040101479 *10 Oct 200327 May 2004Senorx, Inc.Biopsy site marker and process and apparatus for applying it
US20040116806 *21 Nov 200317 Jun 2004Senorx, Inc.Biopsy site marker and process and apparatus for applying it
US20050045192 *16 Sep 20043 Mar 2005Artemis Medical, Inc.Biopsy localization method and device
US20050059887 *16 Sep 200317 Mar 2005Hassan MostafaviLocalization of a target using in vivo markers
US20050059888 *6 Oct 200417 Mar 2005Sirimanne D. LaksenBiopsy cavity marking device and method
US20050063908 *10 Sep 200324 Mar 2005Senorx, Inc.Tissue site markers for in vivo imaging
US20050065453 *3 Aug 200424 Mar 2005Senorx, Inc.Biopsy device with selectable tissue receiving aperture orientation and site illumination
US20050119562 *27 Oct 20042 Jun 2005Senorx, Inc.Fibrous marker formed of synthetic polymer strands
US20050143656 *16 Nov 200430 Jun 2005Senorx, Inc.Cavity-filling biopsy site markers
US20060036159 *30 Sep 200516 Feb 2006Sirimanne D LBiopsy cavity marking device
US20060036165 *29 Sep 200516 Feb 2006Senorx, Inc.Tissue site markers for in vivo imaging
US20060079805 *13 Oct 200413 Apr 2006Miller Michael ESite marker visable under multiple modalities
US20060079829 *18 Nov 200513 Apr 2006Fulton Richard EBiopsy localization method and device
US20060155190 *2 Mar 200613 Jul 2006Senorx, Inc.Imageable biopsy site marker
US20090024225 *16 Jul 200822 Jan 2009Stubbs James BImplant for Targeting Therapeutic Procedure
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US807556810 Jun 200513 Dec 2011Selis James EBiopsy devices and methods
US80755699 Feb 201013 Dec 2011Selis James EBiopsy devices and methods
US831161022 Jan 200913 Nov 2012C. R. Bard, Inc.Biopsy tissue marker
US840162217 Dec 200719 Mar 2013C. R. Bard, Inc.Biopsy marker with in situ-generated imaging properties
US841460227 Jan 20109 Apr 2013James E. SelisBiopsy devices and methods
US845462928 Nov 20114 Jun 2013James E. SelisBiopsy devices and methods
US863931516 May 201328 Jan 2014Senorx, Inc.Marker or filler forming fluid
US867081830 Dec 200811 Mar 2014C. R. Bard, Inc.Marker delivery device for tissue marker placement
US87583696 Jan 201024 Jun 2014James E. SelisBiopsy devices and methods
US90429656 Mar 201326 May 2015C. R. Bard, Inc.Biopsy marker with in situ-generated imaging properties
US904416225 Jan 20132 Jun 2015Senorx, Inc.Marker delivery device with releasable plug
US914934121 Nov 20116 Oct 2015Senorx, IncDeployment of polysaccharide markers for treating a site within a patient
US932706121 Sep 20093 May 2016Senorx, Inc.Porous bioabsorbable implant
US957907712 Dec 200728 Feb 2017C.R. Bard, Inc.Multiple imaging mode tissue marker
US95791595 Nov 201328 Feb 2017Bard Peripheral Vascular, Inc.Apparatus for the percutaneous marking of a lesion
US96228222 Oct 201318 Apr 2017Suros Surgical Systems, Inc.Securement for a surgical site marker and deployment device for same
US20050277871 *10 Jun 200515 Dec 2005Selis James EBiopsy devices and methods
US20100106168 *6 Jan 201029 Apr 2010Selis James EBiopsy devices and methods
US20100130887 *27 Jan 201027 May 2010Selis James EBiopsy devices and methods
US20100145363 *9 Feb 201010 Jun 2010Selis James EBiopsy devices and methods
US20100292711 *9 Feb 201018 Nov 2010James SelisBiopsy devices and methods
US20140171385 *13 Dec 201319 Jun 2014Ecd MedicalMaterials for Short-Term Use in Mammals
USD71544224 Sep 201314 Oct 2014C. R. Bard, Inc.Tissue marker for intracorporeal site identification
USD71594224 Sep 201321 Oct 2014C. R. Bard, Inc.Tissue marker for intracorporeal site identification
USD71645024 Sep 201328 Oct 2014C. R. Bard, Inc.Tissue marker for intracorporeal site identification
USD71645124 Sep 201328 Oct 2014C. R. Bard, Inc.Tissue marker for intracorporeal site identification
EP2931323A4 *13 Dec 20131 Jun 2016Ecd MedicalMaterials for short-term use in mammals
Classifications
U.S. Classification600/431
International ClassificationA61B6/00
Cooperative ClassificationA61B19/54, A61B90/39, A61B2090/3962, A61B2090/3908, A61B2090/3987, A61B2090/3925, A61B2017/00898, A61B2017/00004, A61K9/0024, A61B2017/00831
European ClassificationA61B19/54
Legal Events
DateCodeEventDescription
22 Aug 2008ASAssignment
Owner name: SENORX, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JONES, MICHEL L.;LUBOCK, PAUL;REEL/FRAME:021438/0310;SIGNING DATES FROM 20080326 TO 20080331